BR112022000721A2 - Anticorpos caninizados contra ctla-4 canina - Google Patents
Anticorpos caninizados contra ctla-4 caninaInfo
- Publication number
- BR112022000721A2 BR112022000721A2 BR112022000721A BR112022000721A BR112022000721A2 BR 112022000721 A2 BR112022000721 A2 BR 112022000721A2 BR 112022000721 A BR112022000721 A BR 112022000721A BR 112022000721 A BR112022000721 A BR 112022000721A BR 112022000721 A2 BR112022000721 A2 BR 112022000721A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies against
- against canine
- canine
- caninized
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874287P | 2019-07-15 | 2019-07-15 | |
| US201962926047P | 2019-10-25 | 2019-10-25 | |
| US202063048873P | 2020-07-07 | 2020-07-07 | |
| PCT/EP2020/069923 WO2021009187A1 (en) | 2019-07-15 | 2020-07-15 | Caninized antibodies against canine ctla-4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000721A2 true BR112022000721A2 (pt) | 2022-03-08 |
Family
ID=71620454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000721A BR112022000721A2 (pt) | 2019-07-15 | 2020-07-15 | Anticorpos caninizados contra ctla-4 canina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12435143B2 (https=) |
| EP (1) | EP3999538A1 (https=) |
| JP (2) | JP7757271B2 (https=) |
| CN (2) | CN114174337B (https=) |
| AU (1) | AU2020312686A1 (https=) |
| BR (1) | BR112022000721A2 (https=) |
| CA (1) | CA3145345A1 (https=) |
| WO (1) | WO2021009187A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216131A1 (en) * | 2021-04-21 | 2022-10-27 | Nicola J. MASON | Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) |
| US12263232B1 (en) * | 2024-06-10 | 2025-04-01 | Wyvern Pharmaceuticals Inc. | Composition for regulating production of proteins |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7261890B2 (en) | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| GB201114858D0 (en) | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| CN106029697B (zh) | 2013-12-20 | 2021-06-04 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
| CN107074952B (zh) * | 2014-09-30 | 2021-04-09 | 英特维特国际股份有限公司 | 结合犬pd-l1的pd-l1抗体 |
| US10106107B2 (en) | 2014-11-13 | 2018-10-23 | Mitsubishi Electric Corporation | Waterproof type control unit and waterproof type control unit manufacturing method |
| WO2016183469A1 (en) * | 2015-05-13 | 2016-11-17 | Robert Kirken | Anti-ctla-4 blockade |
| WO2017062615A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
| CA3005696A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
-
2020
- 2020-07-15 CA CA3145345A patent/CA3145345A1/en active Pending
- 2020-07-15 BR BR112022000721A patent/BR112022000721A2/pt unknown
- 2020-07-15 US US17/626,239 patent/US12435143B2/en active Active
- 2020-07-15 EP EP20740612.5A patent/EP3999538A1/en active Pending
- 2020-07-15 JP JP2022502248A patent/JP7757271B2/ja active Active
- 2020-07-15 WO PCT/EP2020/069923 patent/WO2021009187A1/en not_active Ceased
- 2020-07-15 CN CN202080050841.7A patent/CN114174337B/zh active Active
- 2020-07-15 AU AU2020312686A patent/AU2020312686A1/en active Pending
- 2020-07-15 CN CN202411406750.9A patent/CN119241706A/zh active Pending
-
2025
- 2025-07-07 JP JP2025114462A patent/JP2025159730A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12435143B2 (en) | 2025-10-07 |
| CN114174337B (zh) | 2024-10-25 |
| CA3145345A1 (en) | 2021-01-21 |
| AU2020312686A1 (en) | 2022-02-03 |
| JP7757271B2 (ja) | 2025-10-21 |
| JP2022542808A (ja) | 2022-10-07 |
| EP3999538A1 (en) | 2022-05-25 |
| WO2021009187A1 (en) | 2021-01-21 |
| JP2025159730A (ja) | 2025-10-21 |
| CN114174337A (zh) | 2022-03-11 |
| US20220251208A1 (en) | 2022-08-11 |
| CN119241706A (zh) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000604A2 (pt) | Anticorpos caninizados para ctla-4 humana | |
| MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| CO2021004560A2 (es) | Anticuerpos estabilizadores de trem2 | |
| ECSP20007663A (es) | Anticuerpos anti-cd137 | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| BR112022021884A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e clec12a | |
| DOP2018000045A (es) | Anticuerpos pd-l1 | |
| NZ759517A (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
| MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
| BR112019002282A2 (pt) | anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas | |
| MX2017009904A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
| ECSP21085693A (es) | Moléculas de unión a tigit y pd-1/tigit | |
| BR112012015960A2 (pt) | Composições incluindo piruvato para animais de companhia e métodos de uso destas. | |
| MX2020009468A (es) | Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20. | |
| BR112022000721A2 (pt) | Anticorpos caninizados contra ctla-4 canina | |
| NZ731471A (en) | Non-human animals having a humanized cluster of differentiation 47 gene | |
| MX2022007288A (es) | Agentes de union a ilt3 y metodos de uso de los mismos. | |
| MX2024011444A (es) | Anticuerpos anti-npr1 y usos de los mismos. | |
| BR112021022682A2 (pt) | Métodos e composições para prevenir diabetes do tipo 1 | |
| SA519401032B1 (ar) | (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه | |
| NZ757956A (en) | Il4/il13 receptor molecule for veterinary use | |
| BR112022011797A2 (pt) | Anticorpos contra receptor alfa de interleucina-4 canino | |
| BR112022002771A2 (pt) | Anticorpos anti-il31 para uso veterinário | |
| IL277429A (en) | Neutralizing monoclonal antibodies with high affinity for PD-L1 and their uses |